<DOC>
	<DOCNO>NCT01141673</DOCNO>
	<brief_summary>FLT3 overexpression acute myeloid leukemia ( AML ) often cause mutation gene . These mutation cause constitutive phosphorylation FLT3 proteins lead increase proliferation survival , decrease apoptosis resistance chemotherapeutic agent AML cell . There two major type FLT3 mutations- internal tandem duplication ( ITD ) point mutation 835th amino residue . AMLs FLT3 mutation bad prognosis often resistant conventional chemotherapy . Several small molecule compound target FLT3 market clinical trial . Therefore , identification mutation time diagnosis provide good prognostic prediction , might guide treatment selection follow-up strategy . In study , investigator develop sensitive molecular assay detect FLT3 mutation future clinical application . The investigator collect 100 AML sample least 20 sample know FLT3 mutation . The investigator compare assay commonly use method standardize procedure meet requirement clinical pathology laboratory reasonable cost .</brief_summary>
	<brief_title>Development Diagnostic Kit FLT3-ITD Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Patients confirm diagnosis acute myeloid leukemia non</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>FLT3-ITD</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>FLT3</keyword>
	<keyword>D835</keyword>
</DOC>